VBI Vaccines Inc. (VBIV) Reports In-Line Q2 EPS

VBI Vaccines Inc. (NASDAQ: VBIV) reported Q2 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $704.33 thousand.

For earnings history and earnings-related data on VBI Vaccines Inc. (VBIV) click here.

You May Also Be Interested In

• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance
• Innovative Solutions & Support (ISSC) Tops Q3 EPS by 10c